Alternatively spliced circulating tissue factor
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
May 16, 2006
Grant Date -
Mar 13, 2003
app pub date -
Aug 29, 2002
filing date -
Aug 30, 2001
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A new circulating form of soluble human tissue factor was identified. This new form of human tissue factor appears to be the result of alternative splicing and is therefore referred to as 'alt-hTF.' Alt-hTF mRNA was detected in a cell line, HL-60. The cDNA region encoding the entire open reading frame of alt-hTF was cloned. The sequence encoding the alt-hTF mature peptide was expressed in bacteria. alt-hTF consists of the first 166 amino acids of membrane bound TF, and a 40 amino acid C-terminal region unique to alt-hTF. Alt-hTF is likely to be a useful target for compounds to inhibit clotting and to treat disorders associated with elevated TF. It may also be useful as a target for antibodies selectively reactive with alt-hTF, to remove it from the circulation for treatment of clotting or other disorders associated with elevated or abnormal levels of TF, including thrombotic conditions, cardiovascular disorders, DVT, DIC, and possibly metastatic cancers.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully